Sign inSubscribe

target directory

alendronate effervescent oral tablet clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT04403698
Source recordAI-normalized

The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover

It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population.

AI analysis

Indication: Erosive Osteoarthritis

Modality: monoclonal antibody

Target: Alendronate Effervescent Oral Tablet

Sponsor: University Hospital, Ghent

Source URL: ClinicalTrials.gov

Source updated: Dec 13, 2024

Ingested: Jun 18, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Alendronate Effervescent Oral Tablet

View original source fields

Condition raw: Erosive Osteoarthritis

Condition normalized: Erosive Osteoarthritis

Modality raw: monoclonal antibody

Modality normalized: monoclonal antibody

Target raw: Alendronate Effervescent Oral Tablet

Target normalized: Alendronate Effervescent Oral Tablet

Open report